JP4588791B2 - 微粒子油性懸濁液を含む医薬組成物 - Google Patents
微粒子油性懸濁液を含む医薬組成物 Download PDFInfo
- Publication number
- JP4588791B2 JP4588791B2 JP2008558013A JP2008558013A JP4588791B2 JP 4588791 B2 JP4588791 B2 JP 4588791B2 JP 2008558013 A JP2008558013 A JP 2008558013A JP 2008558013 A JP2008558013 A JP 2008558013A JP 4588791 B2 JP4588791 B2 JP 4588791B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- suspension
- pharmaceutical
- average particle
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 44
- 239000000725 suspension Substances 0.000 title claims description 43
- 239000002245 particle Substances 0.000 claims description 70
- 239000004480 active ingredient Substances 0.000 claims description 56
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 41
- 239000010419 fine particle Substances 0.000 claims description 28
- 239000002199 base oil Substances 0.000 claims description 17
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 16
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- -1 2-chloro-6-fluorophenyl Chemical group 0.000 claims description 9
- 239000000375 suspending agent Substances 0.000 claims description 7
- 239000001993 wax Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 239000002270 dispersing agent Substances 0.000 claims description 5
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- QSWVHSZERPYLRU-UHFFFAOYSA-N 3-pyrimidin-4-yl-1,2-oxazole Chemical compound O1C=CC(C=2N=CN=CC=2)=N1 QSWVHSZERPYLRU-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 22
- 230000029142 excretion Effects 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 230000002550 fecal effect Effects 0.000 description 14
- 239000007901 soft capsule Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 11
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 11
- 238000009826 distribution Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 7
- 238000010298 pulverizing process Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229940122696 MAP kinase inhibitor Drugs 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 229940063121 neoral Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 0 **C(N(*)c([o]nc1*)c1-c1ccncc1*)=O Chemical compound **C(N(*)c([o]nc1*)c1-c1ccncc1*)=O 0.000 description 1
- MZIXITYNBSSIAX-UHFFFAOYSA-N 2-(2-bromophenyl)-n-[3-(3-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound CC1=CC=CC(C=2C(=C(NC(=O)CC=3C(=CC=CC=3)Br)ON=2)C=2N=CN=CC=2)=C1 MZIXITYNBSSIAX-UHFFFAOYSA-N 0.000 description 1
- OHMPXDCOVKOOAN-UHFFFAOYSA-N 2-(2-chloro-6-fluorophenyl)-n-[3-(4-fluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2F)Cl)=C1C1=CC=NC=N1 OHMPXDCOVKOOAN-UHFFFAOYSA-N 0.000 description 1
- QOGGUCJFELPAEY-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-(2,4-difluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound FC1=CC(F)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2)Cl)=C1C1=CC=NC=N1 QOGGUCJFELPAEY-UHFFFAOYSA-N 0.000 description 1
- PMRBBABDBAMJIN-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-(2-fluoro-4-methoxyphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound FC1=CC(OC)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2)Cl)=C1C1=CC=NC=N1 PMRBBABDBAMJIN-UHFFFAOYSA-N 0.000 description 1
- BWJBUFSDWGGBFI-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-(3-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound CC1=CC=CC(C=2C(=C(NC(=O)CC=3C(=CC=CC=3)Cl)ON=2)C=2N=CN=CC=2)=C1 BWJBUFSDWGGBFI-UHFFFAOYSA-N 0.000 description 1
- AQMVNECEJJQRQJ-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-(4-chlorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound C1=CC(Cl)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2)Cl)=C1C1=CC=NC=N1 AQMVNECEJJQRQJ-UHFFFAOYSA-N 0.000 description 1
- JZLOFCLTDFXBCB-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-(4-fluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2)Cl)=C1C1=CC=NC=N1 JZLOFCLTDFXBCB-UHFFFAOYSA-N 0.000 description 1
- AELDWGOWMGTPJH-UHFFFAOYSA-N 2-(2-methylphenyl)-n-[3-(3-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound CC1=CC=CC(C=2C(=C(NC(=O)CC=3C(=CC=CC=3)C)ON=2)C=2N=CN=CC=2)=C1 AELDWGOWMGTPJH-UHFFFAOYSA-N 0.000 description 1
- HZMVXCOGADXULI-UHFFFAOYSA-N 2-(3-methylphenyl)-n-[3-(3-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound CC1=CC=CC(CC(=O)NC2=C(C(=NO2)C=2C=C(C)C=CC=2)C=2N=CN=CC=2)=C1 HZMVXCOGADXULI-UHFFFAOYSA-N 0.000 description 1
- 206010000503 Acne cystic Diseases 0.000 description 1
- PJFIMAKNTIRBJV-UHFFFAOYSA-N CC1=CC=CC=C1CC(=O)NC2=C(C=NO2)C3=NC=NC=C3 Chemical compound CC1=CC=CC=C1CC(=O)NC2=C(C=NO2)C3=NC=NC=C3 PJFIMAKNTIRBJV-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000004883 computer application Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- XKEMXPHDWNBNDO-UHFFFAOYSA-N n-[3-(1,3-benzodioxol-4-yl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]-2-(2-chlorophenyl)acetamide Chemical compound ClC1=CC=CC=C1CC(=O)NC1=C(C=2N=CN=CC=2)C(C=2C=3OCOC=3C=CC=2)=NO1 XKEMXPHDWNBNDO-UHFFFAOYSA-N 0.000 description 1
- UZDRQZQLGAILEW-UHFFFAOYSA-N n-[3-(2,4-difluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]-2-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(CC(=O)NC2=C(C(=NO2)C=2C(=CC(F)=CC=2)F)C=2N=CN=CC=2)=C1 UZDRQZQLGAILEW-UHFFFAOYSA-N 0.000 description 1
- JZFXMSKMTAEMOB-UHFFFAOYSA-N n-[3-(2-fluoro-5-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]-2-phenylacetamide Chemical compound CC1=CC=C(F)C(C=2C(=C(NC(=O)CC=3C=CC=CC=3)ON=2)C=2N=CN=CC=2)=C1 JZFXMSKMTAEMOB-UHFFFAOYSA-N 0.000 description 1
- YCKFJJBQSKBYBQ-UHFFFAOYSA-N n-[3-(4-fluoro-3-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NC2=C(C(=NO2)C=2C=C(C)C(F)=CC=2)C=2N=CN=CC=2)=C1 YCKFJJBQSKBYBQ-UHFFFAOYSA-N 0.000 description 1
- 150000005054 naphthyridines Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000008518 pyridopyrimidines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 150000007979 thiazole derivatives Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000008523 triazolopyridines Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
本発明の好ましい態様によれば、該医薬有効成分が難水溶性の医薬有効成分である上記の医薬組成物が提供され、また、別の好ましい態様によれば、該医薬有効成分が炎症性腸疾患の予防及び/又は治療のための医薬有効成分である上記の医薬組成物が提供される。さらに、本発明の別の好ましい態様によれば、該医薬有効成分がp38MAPキナーゼ阻害作用を有する化合物又は生理学的に許容されるその塩である上記の医薬組成物;該医薬有効成分微粒子の平均粒径が10μm以下である上記の医薬組成物;炎症性腸疾患の予防及び/又は治療のために用いる経口投与用の上記医薬組成物が提供される。
5−[(2−クロロフェニル)アセチルアミノ]−3−(4−フルオロフェニル)−4−(4−ピリミジニル)イソオキサゾール、
5−[(2−クロロ−6−フルオロフェニル)アセチルアミノ]−3−(4−フルオロフェニル)−4−(4−ピリミジニル)イソオキサゾール、
3−(4−クロロフェニル)−5−[(2−クロロフェニル)アセチルアミノ]−4−(4−ピリミジニル)イソオキサゾール、
5−[(2−クロロフェニル)アセチルアミノ]−3−(2,4−ジフルオロフェニル)−4−(4−ピリミジニル)イソオキサゾール、
3−(2,4−ジフルオロフェニル)−5−[(3−メチルフェニル)アセチルアミノ]−4−(4−ピリミジニル)イソオキサゾール、
5−[(2−クロロフェニル)アセチルアミノ]−3−(2−フルオロ−4−メトキシフェニル)−4−(4−ピリミジニル)イソオキサゾール、
5−[(2−クロロフェニル)アセチルアミノ]−3−(2,3−メチレンジオキシフェニル)−4−(4−ピリミジニル)イソオキサゾール、
5−[(2−クロロフェニル)アセチルアミノ]−3−(3−メチルフェニル)−4−(4−ピリミジニル)イソオキサゾール、
5−[(2−ブロモフェニル)アセチルアミノ]−3−(3−メチルフェニル)−4−(4−ピリミジニル)イソオキサゾール、
3−(3−メチルフェニル)−5−[(2−メチルフェニル)アセチルアミノ]−4−(4−ピリミジニル)イソオキサゾール、
3−(3−メチルフェニル)−5−[(3−メチルフェニル)アセチルアミノ]−4−(4−ピリミジニル)イソオキサゾール、
3−(2−フルオロ−5−メチルフェニル)−5−(フェニルアセチルアミノ)−4−(4−ピリミジニル)イソオキサゾール、
5−[(3−メトキシフェニル)アセチルアミノ]−3−(3−メチル−4−フルオロフェニル)−4−(4−ピリミジニル)イソオキサゾール、及び
3−(3−メチル−4−フルオロフェニル)−5−[(2−メチルフェニル)アセチルアミノ]−4−(4−ピリミジニル)イソオキサゾール
又はそれらの塩を挙げることができるが、これらに限定されることはない。
例1:医薬有効成分の微粒子化
粉砕条件を種々検討しながら、下記表1に示す平均粒径(メジアン径D50)を有する医薬有効成分の微粒子を得た。ここで、平均粒径は、レーザー回折式粒度分布測定装置LDSA−1400A(東日コンピュータアプリケーションズ)にて粒度分布を測定し算出した。
モノステアリン酸グリセリン200mg及びミツロウ200mgを70℃の水浴中で中鎖脂肪酸トリグリセリド(パナセート)20mLに加えて溶解したものを3つ用意した。
この3つの溶解液を水浴から取り出し、それぞれの溶解液に、平均粒径1.98μmに微粒子化した医薬有効成分937.5mg、1875mg又は3750mgを加え、混合物が室温になるまで撹拌しながら放冷した後、室温にて1分間超音波照射を行い分散化して、3通りの医薬有効成分濃度を有する懸濁液を調製した。これらの懸濁液を00号ゼラチンカプセルに0.8mLずつ充填し、ドリアコーティング機(パウレック製)にて腸溶性フィルム(HPMCP:ヒドロキシプロピルメチルセルロースフタレート、グレード:HP−55)を被覆した。それぞれの腸溶性コーティングカプセルに充填した懸濁液おける内容物の量を、下記例5〜13におけるのと併せて下記表2に示す。
平均粒径3.88μmに微粒子化した医薬有効成分について、例2〜4と同様にして、下記表2に示す3通りの医薬有効成分濃度を有する懸濁液を含む腸溶性コーティングカプセルを調製した。
平均粒径9.59μmに微粒子化した医薬有効成分について、例2〜4と同様にして、下記表2に示す3通りの医薬有効成分濃度を有する懸濁液を含む腸溶性コーティングカプセルを調製した。
平均粒径19.76μmに微粒子化した医薬有効成分について、例2〜4と同様にして、下記表2に示す3通りの医薬有効成分濃度を有する懸濁液を含む腸溶性コーティングカプセルを調製した。
平均粒径1.98μmに微粒子化した医薬有効成分を用い、例2〜4と同様にして、下記表3に示す3通りの医薬有効成分濃度を有する懸濁液を調製した。次いで、二重管ノズルに懸濁液及びゼラチン溶液を入れ、シームレスソフトカプセル製造機を用いて、液中滴下法によりカプセル化した。得られたカプセルから凝固油を常法にて脱油後、速やかにドラム乾燥し、直径2.0mm、皮膜率30%、1カプセル中の内容量約3μLのシームレスソフトカプセルを製造した。なお、懸濁液の内容物の量を、例17〜18におけるのと併せて下記表3に示す。
平均粒径19.76μmに微粒子化した医薬有効成分を用い、例14〜16と同様にして、下記表3に示す2通りの医薬有効成分濃度を有する懸濁液を含むシームレスソフトカプセルを調製した。
一晩絶食させた雄ビーグル犬(体重10〜15kg、各粒径の各濃度についてn=3、ただし平均粒径19.76μmの医薬有効成分についての46.9mg/mLの濃度及び平均粒径19.76μmの医薬有効成分についての93.8mg/mLの濃度についてはn=5)に、前記例2〜13で調製した腸溶性コーティングカプセルを、有効成分の投与量として150mgとなるように1〜4カプセルずつ精製水30mLとともに経口投与した 。なお、比較例として、平均粒径1.98μmの医薬有効成分を乳糖と混合して倍散にしたもの(300mgを00号カプセルに充填、有効成分の投与量としては150mg)を、同様にしてイヌに経口投与した。
前記例14及び15で調製したシームレスソフトカプセル、すなわち、平均粒径1.98μmの医薬有効成分を50mg/mL又は100mg/mLの濃度で含有するシームレスソフトカプセルについて、例19と同様にして、イヌに20mg又は100mgを経口投与し(各濃度及び各投与量についてn=3)、医薬有効成分の糞中***率を測定した。この結果を下記表5に示す。
Claims (6)
- 炎症性腸疾患の予防及び/又は治療に用いるための平均粒径20μm以下の医薬有効成分微粒子の基剤油中懸濁液を含む経口投与用の医薬組成物であって、医薬有効成分が5−[(2−クロロ−6−フルオロフェニル)アセチルアミノ]−3−(4−フルオロフェニル)−4−(4−ピリミジニル)イソオキサゾール又は生理学的に許容されるその塩であり、該医薬有効成分を腸管内の局所に滞留させて該局所で作用させるために用いる医薬組成物。
- 医薬有効成分微粒子の平均粒径が10μm以下である請求項1に記載の医薬組成物。
- 該懸濁液中に懸濁化剤、ワックス類、及び分散剤からなる群から選ばれる1種類又は2種類以上の製剤用添加物を含む請求項1又は2に記載の医薬組成物。
- 医薬有効成分を該懸濁液全質量に対して1〜30質量%の範囲で含む請求項1ないし3のいずれか1項に記載の医薬組成物。
- 基剤油を該懸濁液全質量に対して70〜99質量%の範囲で含む請求項1ないし4のいずれか1項に記載の医薬組成物。
- 基剤油が中鎖脂肪酸トリグリセリドである請求項1ないし5のいずれか1項に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007035916 | 2007-02-16 | ||
JP2007035916 | 2007-02-16 | ||
PCT/JP2008/000230 WO2008099615A1 (ja) | 2007-02-16 | 2008-02-15 | 微粒子油性懸濁液を含む医薬組成物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010040362A Division JP2010120974A (ja) | 2007-02-16 | 2010-02-25 | 微粒子油性懸濁液を含む医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2008099615A1 JPWO2008099615A1 (ja) | 2010-05-27 |
JP4588791B2 true JP4588791B2 (ja) | 2010-12-01 |
Family
ID=39689861
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008558013A Expired - Fee Related JP4588791B2 (ja) | 2007-02-16 | 2008-02-15 | 微粒子油性懸濁液を含む医薬組成物 |
JP2010040362A Pending JP2010120974A (ja) | 2007-02-16 | 2010-02-25 | 微粒子油性懸濁液を含む医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010040362A Pending JP2010120974A (ja) | 2007-02-16 | 2010-02-25 | 微粒子油性懸濁液を含む医薬組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8309138B2 (ja) |
EP (1) | EP2123255B1 (ja) |
JP (2) | JP4588791B2 (ja) |
KR (1) | KR101434706B1 (ja) |
CN (1) | CN101610754A (ja) |
AU (1) | AU2008215659B2 (ja) |
CA (1) | CA2677842C (ja) |
ES (1) | ES2423929T3 (ja) |
WO (1) | WO2008099615A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ591810A (en) | 2008-09-17 | 2012-12-21 | Chiasma Inc | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid |
CN103655512B (zh) * | 2013-12-12 | 2015-05-20 | 海南海力制药有限公司 | 一种硝酸芬替康唑***软胶囊及其制备方法 |
MA41462A (fr) | 2015-02-03 | 2021-05-12 | Chiasma Inc | Méthode de traitement de maladies |
EP3659626A4 (en) * | 2017-07-26 | 2021-05-05 | The Doshisha | MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF CONDITIONS RELATED TO THE TGF- SIGNALING ROUTE, AND ITS APPLICATION |
EP3668957A4 (en) * | 2017-08-17 | 2021-06-02 | University of Delaware | FURAN-BASED COMPOSITIONS AND PROCESS FOR THEIR MANUFACTURING |
CN114748622A (zh) | 2017-10-05 | 2022-07-15 | 弗尔康医疗公司 | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8546591A (en) | 1990-09-13 | 1992-04-15 | Smithkline Beecham Corporation | Non-aqueous liquid oral suspensions |
IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
JPH0616556A (ja) | 1992-07-02 | 1994-01-25 | Yoshitomi Pharmaceut Ind Ltd | 難溶性薬物含有製剤 |
US5651983A (en) | 1993-02-26 | 1997-07-29 | The Procter & Gamble Company | Bisacodyl dosage form for colonic delivery |
US5656290A (en) * | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
JPH07138151A (ja) | 1993-11-15 | 1995-05-30 | Kanebo Ltd | ソフトカプセル剤及びその製造方法 |
ES2183935T3 (es) * | 1995-02-13 | 2003-04-01 | Searle & Co | Isoxazoles sustituidos para el tratamiento de la inflamacion. |
JPH1081621A (ja) | 1996-04-01 | 1998-03-31 | Takeda Chem Ind Ltd | 経口投与用医薬組成物 |
EP0925061B1 (en) | 1996-08-22 | 2005-12-28 | Jagotec Ag | Compositions comprising microparticles of water-insoluble substances and method for preparing same |
US5736151A (en) | 1996-12-09 | 1998-04-07 | Pharmacia & Upjohn Company | Antibiotic oil suspensions |
WO1998052940A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
AU735084B2 (en) * | 1998-02-09 | 2001-06-28 | Joel Bolonick | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
JPH11302156A (ja) | 1998-04-16 | 1999-11-02 | Tanabe Seiyaku Co Ltd | ポリペプチドの微粒子化方法 |
JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | 5−アミノイソキサゾール誘導体 |
PE20001227A1 (es) | 1998-10-30 | 2000-11-06 | Hoffmann La Roche | Procesos para producir una composicion de isotretinoina |
DE69911993T2 (de) * | 1998-12-23 | 2004-05-19 | Amgen Inc., Thousand Oaks | Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen |
WO2000039116A1 (fr) | 1998-12-25 | 2000-07-06 | Teikoku Hormone Mfg. Co., Ltd. | Derives d'aminopyrazole |
JP2002534371A (ja) | 1999-01-06 | 2002-10-15 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物 |
SK286371B6 (sk) | 1999-02-23 | 2008-08-05 | Merck & Co., Inc. | Farmaceutický prostriedok |
SK286666B6 (sk) | 1999-04-23 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 5-Pyridyl-1,3-azolové zlúčeniny, spôsob výroby a použitia |
CA2386277A1 (en) | 1999-10-01 | 2001-04-12 | Natco Pharma Limited | An improved pharmaceutical composition and a process for its preparation |
IN192188B (ja) | 2000-06-16 | 2004-03-13 | Ranbaxy Lab Ltd | |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
DE60104206T2 (de) * | 2000-09-22 | 2005-09-22 | Galephar M/F | Halbfeste arzneizubereitung enthaltend isotretinoin |
EP1455752A2 (en) | 2001-12-20 | 2004-09-15 | Pharmacia Corporation | Pharmaceutical suspension for oral administration |
AU2003230692A1 (en) * | 2002-03-20 | 2003-10-08 | Elan Pharma International Ltd. | Nanoparticulate compositions of map kinase inhibitors |
GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
JP4252534B2 (ja) | 2002-08-06 | 2009-04-08 | エフ.ホフマン−ラ ロシュ アーゲー | p−38MAPキナーゼインヒビターとしての6−アルコキシ−ピリド−ピリミジン類 |
DE10237883A1 (de) | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
TW200412948A (en) | 2002-08-23 | 2004-08-01 | Ionix Pharmaceuticals Ltd | Therapeutic compounds |
JP2004099442A (ja) | 2002-09-04 | 2004-04-02 | Nisshin Pharma Inc | 難溶性薬物含有製剤およびその製造方法 |
EP1546141A1 (en) | 2002-09-06 | 2005-06-29 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use in the treatment of ischemic diseases |
MXPA05006670A (es) | 2002-12-18 | 2005-10-19 | Algorx Pharmaceuticals Inc | Administracion de capsaicinoides. |
WO2004072072A1 (en) | 2003-02-14 | 2004-08-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
PL378111A1 (pl) | 2003-02-14 | 2006-03-06 | Smithkline Beecham Corporation | Nowe związki |
JPWO2004073692A1 (ja) | 2003-02-18 | 2006-06-01 | 山下 伸二 | 難水溶性薬物のハードカプセル剤 |
JP2005013938A (ja) | 2003-06-27 | 2005-01-20 | Canon Inc | 脱色装置及び方法 |
WO2005013938A1 (ja) | 2003-08-06 | 2005-02-17 | Eisai Co., Ltd. | 薬物超微粒子の製造法及び製造装置 |
JP5096658B2 (ja) * | 2003-10-06 | 2012-12-12 | 株式会社三協 | 生物学的利用能を向上させたソフトカプセル |
GB0402143D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
CN1926139A (zh) | 2004-02-27 | 2007-03-07 | 霍夫曼-拉罗奇有限公司 | 稠合吡唑衍生物 |
DK1742618T3 (da) * | 2004-05-04 | 2012-10-01 | Hormos Medical Ltd | Flydende orale formuleringer af ospemifen |
US8758821B2 (en) * | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
JP5100126B2 (ja) | 2004-12-28 | 2012-12-19 | あすか製薬株式会社 | ピリミジニルイソオキサゾール誘導体 |
JP2007039408A (ja) | 2005-08-05 | 2007-02-15 | Unitec Foods Co Ltd | 微粉化クレアチンとその製造方法 |
-
2008
- 2008-02-15 AU AU2008215659A patent/AU2008215659B2/en active Active
- 2008-02-15 US US12/526,825 patent/US8309138B2/en active Active
- 2008-02-15 JP JP2008558013A patent/JP4588791B2/ja not_active Expired - Fee Related
- 2008-02-15 KR KR1020097019114A patent/KR101434706B1/ko active IP Right Grant
- 2008-02-15 EP EP08710384.2A patent/EP2123255B1/en active Active
- 2008-02-15 CN CNA2008800051218A patent/CN101610754A/zh active Pending
- 2008-02-15 ES ES08710384T patent/ES2423929T3/es active Active
- 2008-02-15 WO PCT/JP2008/000230 patent/WO2008099615A1/ja active Application Filing
- 2008-02-15 CA CA2677842A patent/CA2677842C/en active Active
-
2010
- 2010-02-25 JP JP2010040362A patent/JP2010120974A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2008215659B2 (en) | 2012-11-01 |
US8309138B2 (en) | 2012-11-13 |
CA2677842C (en) | 2014-09-16 |
WO2008099615A1 (ja) | 2008-08-21 |
US20100092565A1 (en) | 2010-04-15 |
JP2010120974A (ja) | 2010-06-03 |
CA2677842A1 (en) | 2008-08-21 |
KR20090117894A (ko) | 2009-11-13 |
ES2423929T3 (es) | 2013-09-25 |
KR101434706B1 (ko) | 2014-08-26 |
EP2123255A4 (en) | 2010-06-02 |
JPWO2008099615A1 (ja) | 2010-05-27 |
AU2008215659A1 (en) | 2008-08-21 |
EP2123255B1 (en) | 2013-05-15 |
CN101610754A (zh) | 2009-12-23 |
EP2123255A1 (en) | 2009-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4588791B2 (ja) | 微粒子油性懸濁液を含む医薬組成物 | |
JP3903061B2 (ja) | 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤 | |
ES2496144T3 (es) | Formulación de cápsulas de pirfenidona y excipientes farmacéuticamente aceptables | |
KR101454086B1 (ko) | 이마티닙 메실레이트의 안정화된 무정형 형태 | |
TW200821298A (en) | Pharmaceutical compositions | |
ES2883448T3 (es) | Composiciones farmacéuticas mejoradas de pimobendán | |
Zhou et al. | Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine | |
US20080145431A1 (en) | Medicinal Composition and Process for Producing the Same | |
JP2015510935A (ja) | 封入ジエチレントリアミンペンタアセテート粒子の経口送達のための組成物および方法 | |
JP5300477B2 (ja) | 薬理活性物質の吸収性が改善された医薬組成物 | |
CN105997927A (zh) | 谷维素纳米结晶胶囊剂及其制备工艺 | |
WO2007052738A1 (ja) | 薬物の吸収性が改善された医薬組成物 | |
CN1615899B (zh) | 葛根素口服制剂 | |
KR101096429B1 (ko) | 안정성이 향상된 아세클로페낙의 경구용 연질캅셀제 | |
US20180228734A1 (en) | Compositions of gallium (iii) complexes for oral administration | |
KR101476096B1 (ko) | 용해도가 향상된 쎄레콕시브의 약제학적 조성물 | |
TWI597063B (zh) | 藥物組成物及其製備方法 | |
JP5106119B2 (ja) | シクロオキシゲナーゼ−2阻害剤を含む経口投与用の薬剤、およびその調製方法 | |
JPS6136217A (ja) | 経口投与用持効性製剤 | |
JP6935987B2 (ja) | 医薬組成物 | |
JP2004519489A (ja) | 薬剤組成物 | |
JP2018044017A (ja) | 粒子製剤 | |
JPWO2020045456A1 (ja) | 薬物含有粒子 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100225 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100407 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100907 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100908 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4588791 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130917 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |